Prevention of lyme disease: promising research or sisyphean task?
Language English Country Poland Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Antigenic Variation MeSH
- Antigens, Bacterial immunology metabolism MeSH
- Antigens, Surface immunology MeSH
- Autoimmune Diseases etiology MeSH
- Bacterial Proteins immunology metabolism MeSH
- Bacterial Vaccines immunology MeSH
- Borrelia burgdorferi * immunology metabolism MeSH
- Ixodes immunology metabolism microbiology MeSH
- Humans MeSH
- Lipoproteins immunology metabolism MeSH
- Lyme Disease * immunology microbiology pathology prevention & control MeSH
- Molecular Sequence Data MeSH
- Mice MeSH
- Bacterial Outer Membrane Proteins immunology MeSH
- Antibodies, Bacterial immunology MeSH
- Vaccination adverse effects MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Geographicals
- United States MeSH
- Names of Substances
- Antigens, Bacterial MeSH
- Antigens, Surface MeSH
- Bacterial Proteins MeSH
- Bacterial Vaccines MeSH
- Lipoproteins MeSH
- OspA protein MeSH Browser
- OspB protein, Borrelia burgdorferi MeSH Browser
- Bacterial Outer Membrane Proteins MeSH
- Antibodies, Bacterial MeSH
- VlsE protein, Borrelia burgdorferi MeSH Browser
Borrelia burgdorferi sensu lato (Spirochaetes) is a group of at least 12 closely related species, some of which are responsible for chronic zoonotic infection that may cause Lyme disease. The only experimentally confirmed vector transmitting Borrelia to mammals is the Ixodes ticks. Borrelia is a highly adapted pathogen that can survive in the host organism in spite of the intense immune responses. Some patients have chronic long-lasting complications despite antibiotic therapy, probably due to adverse effects of the immune responses. A preventive vaccine against this bacterium has not been available due to the relatively broad spectrum and antigenic variability of Borrelia-surface lipoproteins and the different epitope recognition by experimental animals and humans. Although a human vaccine was marketed in the USA, it has been already pulled off the market. In addition, this vaccine was effective only in the USA, where the only pathogenic species is B. burgdorferi sensu stricto. Recent data indicate that a broadly effective vaccine will to be composed of a mixture of several antigens or multiple epitopes.
References provided by Crossref.org
Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome